CN101626766B - 药用组合物的改进和与药用组合物相关的改进 - Google Patents

药用组合物的改进和与药用组合物相关的改进 Download PDF

Info

Publication number
CN101626766B
CN101626766B CN2008800068666A CN200880006866A CN101626766B CN 101626766 B CN101626766 B CN 101626766B CN 2008800068666 A CN2008800068666 A CN 2008800068666A CN 200880006866 A CN200880006866 A CN 200880006866A CN 101626766 B CN101626766 B CN 101626766B
Authority
CN
China
Prior art keywords
buprenorphine
naloxone
composition
patient
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800068666A
Other languages
English (en)
Chinese (zh)
Other versions
CN101626766A (zh
Inventor
克利斯托弗·波恩·夏普利奥
尼尔·海德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reckitt Benckiser Healthcare UK Ltd
Original Assignee
Rb Pharmaceutical Co ltd
Reckitt Benckiser Healthcare UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rb Pharmaceutical Co ltd, Reckitt Benckiser Healthcare UK Ltd filed Critical Rb Pharmaceutical Co ltd
Publication of CN101626766A publication Critical patent/CN101626766A/zh
Application granted granted Critical
Publication of CN101626766B publication Critical patent/CN101626766B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2008800068666A 2007-03-01 2008-02-15 药用组合物的改进和与药用组合物相关的改进 Expired - Fee Related CN101626766B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0703968A GB2447016A (en) 2007-03-01 2007-03-01 Buprenorphine/naloxone compositions
GB0703968.8 2007-03-01
PCT/GB2008/000526 WO2008104738A1 (en) 2007-03-01 2008-02-15 Improvements in and relating to medicinal compositions

Publications (2)

Publication Number Publication Date
CN101626766A CN101626766A (zh) 2010-01-13
CN101626766B true CN101626766B (zh) 2013-07-10

Family

ID=37965735

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800068666A Expired - Fee Related CN101626766B (zh) 2007-03-01 2008-02-15 药用组合物的改进和与药用组合物相关的改进

Country Status (16)

Country Link
US (1) US20110046172A1 (cg-RX-API-DMAC10.html)
EP (1) EP2129380A1 (cg-RX-API-DMAC10.html)
JP (2) JP2010520186A (cg-RX-API-DMAC10.html)
KR (1) KR20090117891A (cg-RX-API-DMAC10.html)
CN (1) CN101626766B (cg-RX-API-DMAC10.html)
AR (1) AR065579A1 (cg-RX-API-DMAC10.html)
AU (1) AU2008220574A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0807908A2 (cg-RX-API-DMAC10.html)
CA (1) CA2678582A1 (cg-RX-API-DMAC10.html)
CL (1) CL2008000606A1 (cg-RX-API-DMAC10.html)
GB (1) GB2447016A (cg-RX-API-DMAC10.html)
MX (1) MX2009009131A (cg-RX-API-DMAC10.html)
PE (1) PE20090168A1 (cg-RX-API-DMAC10.html)
TW (1) TWI451868B (cg-RX-API-DMAC10.html)
WO (1) WO2008104738A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200905664B (cg-RX-API-DMAC10.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
US8475832B2 (en) * 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US9277748B2 (en) * 2010-03-12 2016-03-08 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Agonist/antagonist compositions and methods of use
US8529914B2 (en) * 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
MX352959B (es) * 2011-08-18 2017-12-15 Biodelivery Sciences Int Inc Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina.
ME02153B (me) 2011-09-19 2015-10-20 Orexo Ab Nove farmaceutske kompozicije, otporne na zloupotrebu, za tretman zavisnosti od opioida
SG10202012743WA (en) * 2011-12-21 2021-01-28 Biodelivery Sciences Int Inc Transmucosal drug delivery devices for use in chronic pain relief
CN103690495B (zh) * 2013-12-19 2015-04-08 贵州景峰注射剂有限公司 注射用盐酸纳洛酮的冷冻干燥方法
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
AU2015228541B2 (en) 2014-03-14 2020-09-03 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
CN122182527A (zh) 2016-05-05 2026-06-12 阿奎斯蒂弗医疗股份有限公司 增强递送的肾上腺素组合物
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
WO2023076281A1 (en) 2021-10-25 2023-05-04 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1185317A (zh) * 1996-07-19 1998-06-24 日东电工株式会社 丁丙诺啡经皮吸收剂
WO2001035942A3 (en) * 1999-11-19 2002-06-13 Reckitt Benckiser Healthcare Analgesic compositions containing buprenorphine
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
PT1526848E (pt) * 2002-08-09 2007-08-08 Gruenenthal Gmbh Antagonistas dos receptores de opióides em sistemas transdérmicos contendo buprenorfina

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1185317A (zh) * 1996-07-19 1998-06-24 日东电工株式会社 丁丙诺啡经皮吸收剂
WO2001035942A3 (en) * 1999-11-19 2002-06-13 Reckitt Benckiser Healthcare Analgesic compositions containing buprenorphine
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine

Also Published As

Publication number Publication date
CN101626766A (zh) 2010-01-13
KR20090117891A (ko) 2009-11-13
CA2678582A1 (en) 2008-09-04
CL2008000606A1 (es) 2008-10-03
AR065579A1 (es) 2009-06-17
HK1139871A1 (en) 2010-09-30
US20110046172A1 (en) 2011-02-24
TW200843773A (en) 2008-11-16
ZA200905664B (en) 2010-10-27
TWI451868B (zh) 2014-09-11
WO2008104738A1 (en) 2008-09-04
GB0703968D0 (en) 2007-04-11
AU2008220574A1 (en) 2008-09-04
EP2129380A1 (en) 2009-12-09
JP2014196325A (ja) 2014-10-16
JP2010520186A (ja) 2010-06-10
PE20090168A1 (es) 2009-03-19
MX2009009131A (es) 2009-09-03
BRPI0807908A2 (pt) 2014-06-17
GB2447016A (en) 2008-09-03

Similar Documents

Publication Publication Date Title
TWI451868B (zh) 醫藥組成物之改良及相關之改良
EP2125019B1 (en) Improved medicinal compositions comprising buprenorphine and naltrexone
CN101622012B (zh) 包含丁丙诺啡和纳美芬的改善的药用组合物
EP2258353A2 (en) Dosage form containing oxycodone and naloxone
HK1139871B (en) Improvements in and relating to medicinal compositions
AU2014201777A1 (en) Improvements in and relating to medicinal compositions
AU2014201782A1 (en) Improved medicinal compositions comprising buprenorphine and naltrexone
HK1139867A (en) Improved medicinal compositions comprising buprenorphine and naltrexone
HK1139868B (en) Improved medicinal compositions comprising buprenorphine and nalmefene

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1139871

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: RB MEDICAL LTD.

Free format text: FORMER OWNER: RECKITT BENCKISER HEALTHCARE (UK) LIMITED

Effective date: 20121226

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20121226

Address after: Burke County, England

Applicant after: RECKITT BENCKISER HEALTHCARE (UK) LIMITED

Address before: Burke County, England

Applicant before: Reckitt & Benksl Health-Care (England) Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1139871

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130710

Termination date: 20170215

CF01 Termination of patent right due to non-payment of annual fee